Uterine Cancer Diagnostic Testing Market Forecast
- Uterine cancer diagnostic testing market size projected to reach US$6.56 Bn by 2031, showing significant growth from US$3.23 Bn estimated in 2024
- Global uterine cancer diagnostic testing market revenue poised to exhibit a notable CAGR of 13.5% during 2024-2031
Uterine Cancer Diagnostic Testing Market Insights
- Endometrial biopsy is the gold standard for diagnosing endometrial cancer.
- The rising prevalence of uterine cancer is driving the global uterine cancer diagnostics testing market growth.
- Technological advancements in genetic testing, biomarker identification, and imaging methods have increased diagnostic accuracy.
- Demand for diagnostic testing among older women is predicted to rise.
- Public health campaigns and initiatives promoting women's health issues and early detection contribute to the market expansion.
- Endometrial carcinoma dominates uterine cancer diagnostic testing market due to greater accuracy and accessibility.
- Diagnostic laboratories lead the market with specialized equipment and skilled professionals.
- North America, particularly the US, dominates the market driven by high incidence of uterine cancer.
- China emerges as a key market in Asia Pacific due to increased healthcare expenditure and government support.
- Europe's rising uterine cancer cases fuel market growth for diagnostic testing.
A Look Back and a Look Forward – Comparative Analysis
Pre-2023, the uterine cancer diagnostic testing market was experiencing steady growth. PMR's industry assessment, the market was projected to expand at a CAGR of 8.5% from 2019 to 2023. The market was driven by factors such as rising awareness about uterine cancer, increasing cases of uterine cancer, innovation in drug development, and technological advancements
Post-2024, the market is expected to continue its growth trajectory. The market size is projected to reach US$ 3.23 Bn in 2024 and is expected to obtain US$ 6.56 Bn by 2031, growing at a CAGR of 13.5% during the forecast period. The integration of precision medicine and digital health solutions was identified as an opportunity for industry growth.
Additionally, ongoing research and development efforts focused on novel treatment modalities, drug delivery systems, and prognostic tools were expected to shape the future of the uterine cancer market. Efforts to address existing disparities in uterine cancer diagnosis and treatment access were also likely to influence industry trends.
Further, uterine cancer diagnostic testing market trends, such as rising incidence rates, technological advancements, and awareness of women's health issues, are fueling the industry demand.
Key Growth Determinants
Increasing Incidence of Uterine Cancer
The increasing incidence of uterine cancer is a significant driver for the uterine cancer diagnostic testing market expansion. Uterine cancer is one of the most common gynecological cancers, and its prevalence has been rising globally. Factors such as hormonal imbalances, obesity, and a sedentary lifestyle contribute to the increasing incidence.
As the number of cases continues to rise, there is a growing need for accurate and efficient diagnostic tests for early detection and effective treatment planning. This drives uterine cancer diagnostic testing sales, including imaging tests, biopsies, and molecular testing, leading to market growth.
Advancements in Diagnostic Technologies
Advancements in diagnostic technologies play a crucial role in boosting the uterine cancer diagnostic testing market revenue. The development of innovative diagnostic tools and techniques enhances the accuracy, sensitivity, and specificity of uterine cancer detection. For instance, imaging techniques such as transvaginal ultrasound, magnetic resonance imaging (MRI), and positron emission tomography (PET) provide detailed visualization of the uterus, aiding in the identification of tumors and metastasis.
Molecular testing, including genetic and genomic profiling, helps assess risk factors and determine personalized treatment strategies. These technological advancements not only improve diagnostic accuracy but also enable early detection, leading to improved patient outcomes and driving industry growth.
Increasing Awareness and Screening Initiatives
Growing awareness about uterine cancer and the importance of early detection is another significant driver for boosting uterine cancer diagnostic testing market shares. Efforts by healthcare organizations, government bodies, and advocacy groups to raise awareness about the risk factors, symptoms, and screening options for uterine cancer have led to increased screening rates.
Screening initiatives, such as Pap smears, endometrial biopsies, and HPV testing, help in the early detection of uterine cancer, enabling timely intervention and improved survival rates. The emphasis on regular check-ups and preventive healthcare measures has resulted in a higher demand for uterine cancer diagnostic testing. As awareness continues to grow, more individuals are likely to undergo screening, driving the market for uterine cancer testing.
Key Growth Barriers
High Costs and Inadequate Reimbursement
One of the key restraints for the uterine cancer diagnostic testing market value is the high costs associated with diagnostic tests and inadequate reimbursement policies. Diagnostic tests for uterine cancer, such as imaging tests, biopsies, and molecular testing, can be expensive, making them less accessible to certain patient populations.
Additionally, the lack of adequate reimbursement for these tests can further limit patient access and affordability. High costs and inadequate reimbursement can hinder market growth by limiting the adoption of diagnostic tests and reducing the overall demand for uterine cancer diagnostic testing.
Limited Awareness and Screening Programs
As per the uterine cancer diagnostic testing market research report, limited awareness and screening programs pose another challenge to the growth of the market. Uterine cancer may not receive the same level of attention and awareness as some other types of cancer, leading to lower screening rates and delayed diagnoses.
Lack of awareness about the risk factors, symptoms, and importance of early detection can result in missed opportunities for timely diagnosis and treatment. Insufficient screening programs and initiatives can further contribute to under diagnosis and hinder the growth of opportunities for industry players. Increasing awareness among healthcare providers and the general population about the importance of uterine cancer screening and early detection is crucial to overcome this restraint and drive market growth.
Uterine Cancer Diagnostic Testing Market Trends and Opportunities
- Non-Invasive and Blood-Based Diagnostic Tests
One notable industry trend in the diagnostic testing industry for uterine cancer is the shift towards non-invasive and blood-based diagnostic tests. Traditional diagnostic methods for uterine cancer, such as biopsies and imaging tests, can be invasive and uncomfortable for patients. However, advancements in technology have led to the development of non-invasive alternatives that offer convenience and reduce patient discomfort.
As per Fairfield's uterine cancer diagnostic testing market update, blood-based tests, such as liquid biopsies, are gaining prominence as they allow for the detection of specific biomarkers associated with uterine cancer through a simple blood sample. These tests offer the potential for early detection, monitoring treatment response, and assessing disease progression.
- Precision Medicine and Digital Health Solutions
An opportunity for the uterine cancer diagnostic testing industry lies in the integration of precision medicine and digital health solutions. Precision medicine aims to tailor medical treatment to individual patients based on their genetic makeup, lifestyle, and environmental factors. In the context of uterine cancer, precision medicine approaches can help identify specific genetic mutations or biomarkers that influence disease progression and treatment response.
By integrating precision medicine with digital health solutions, such as electronic health records, telemedicine, and data analytics, healthcare providers can enhance the efficiency and effectiveness of uterine cancer diagnostic testing. This integration enables seamless data sharing, real-time monitoring, and personalized treatment decision-making.
Furthermore, it facilitates the collection and analysis of large-scale patient data, contributing to research and the development of innovative diagnostic tools and therapies. The integration of precision medicine and digital health solutions presents various uterine cancer diagnostic testing market opportunities to improve patient outcomes, optimize resource utilization, and drive advancements in the market.
How Does Regulatory Scenario Shape this Industry?
The regulatory scenario for the uterine cancer diagnostic testing industry is shaped by various factors and considerations. Stringent regulatory frameworks exist globally, which impact the growth of the cancer diagnostics market. These regulations ensure that diagnostic tests meet certain standards of safety, efficacy, and accuracy. However, these regulations can also pose challenges to market growth, as they may increase the time and cost required for product approvals.
In terms of regional dynamics, Asia Pacific, including countries like China, India, and Japan, is likely to display strong uterine cancer diagnostic testing market growth due to factors such as a large patient pool, availability of experienced technicians at reduced costs, and clear regulatory environments that encourage quicker product approvals.
Furthermore, advancements in screening technologies and the development of new diagnostic tools and genomic profiling tests are driving the market demand. These advancements enable a more personalized approach to treatment, improving efficacy and reducing side effects.
Segments Covered in Uterine Cancer Diagnostic Testing Market Report
- Endometrial Carcinoma Dominates on the Back of Greater Accuracy and Accessibility
The uterine cancer diagnostic testing market forecast shows significant growth, with a focus on categorizing cancer types into endometrial carcinoma and uterine sarcoma, with endometrial carcinoma expected to hold a dominant market share of 91.2% in 2024. This category focuses on improving the accuracy and accessibility of diagnostic techniques to enhance patient outcomes and drive further advancements in uterine cancer diagnostics.
Additionally, biopsy procedures are projected to hold a substantial market share of 56.1%. Biopsies play a crucial role in diagnosing uterine cancer by extracting tissue samples for examination and analysis.
- Diagnostic Laboratories Lead with Specialized Equipment and Skilled Physicians
The uterine cancer diagnostic testing market is characterized by different end users, including hospitals, ambulatory surgical centers, cancer research centers, specialized clinics, and diagnostic laboratories. Among these, diagnostic laboratories are expected to dominate the market, holding a substantial market share of 41.3% in 2024.
Diagnostic laboratories play a vital role in the uterine cancer diagnostic testing process. They are equipped with specialized equipment and skilled personnel who perform various tests and analyses to accurately diagnose uterine cancer. These laboratories offer a range of diagnostic services, including ultrasound scanning, biopsies, and blood tests, providing comprehensive and reliable results to healthcare professionals.
Regional Frontrunners
- US Dominates with Growing Incidence and Cost-effective Solutions
The North America Uterine Cancer Diagnostics & Treatment Market was estimated to reach US$9.18 billion in 2024, with a projected growth rate of 4.22%. The U.S. is set to lead the uterine cancer diagnostic testing market in North America, driven by a rising incidence of uterine cancer. Unhealthy lifestyles and the growing obese population contribute to the high incidence of uterine cancer, as highlighted by the National Institutes of Health. Additionally, the increasing number of post-menopausal women further contributes to the prevalence of this disease.According to the U.S. Census Bureau, women aged 65 and above accounted for a significant portion of the elderly population, while a substantial percentage of women between 25 and 99 years belonged to the age group of 50-99 years, according to 2017 world population statistics.
- China Emerges as the Key Market in Asia Pacific
China is the second dominant market for uterine cancer diagnostic testing in the Asia Pacific region. The growth is driven by increased healthcare expenditure and government funding in the country. The government's reimbursement policies for women's health screenings and treatment further contribute to the market's expansion.
China's large population, coupled with a growing number of post-menopausal women, creates a higher demand for comprehensive diagnostic services. According to data from the National Central Cancer Registry of China (NCCR), the incidence and mortality rates of cancer have been rapidly increasing, with uterine cancer ranking as the second most common type of gynecologic cancer in the country.
- Rising Uterine Cancer Cases Drive Market Growth in Europe
The increasing number of uterine cancer cases in Europe is expected to fuel the growth of the market for uterine cancer diagnostic testing in the region. According to the European Society for Medical Oncology, the U.K. registers approximately 7,400 new cases annually, while the European Union sees 88,068 new cases each year. Additionally, the Cancer Registry of Norway reveals that more than one in 20 gynecologic cancer cases are of endometrial cancer. These analysis and studies indicate that the uterine cancer diagnostic testing market shares are expected to reach notable growth.
Recent Industry Developments
- In April 2024, the All India Institute of Medical Sciences (AIIMS) launched a multicentre study to develop low-cost human papillomavirus (HPV) tests for cervical cancer screening. The tests, supported by DBT-BIRAC Grand Challenges India and the World Health Organizations’ International Agency for Research on Cancer, will be validated at AIIMS New Delhi, NICPR Noida, and NIRRCH Mumbai. Cervical cancer is the fourth most common cancer in women globally.
- In February 2024, Kauvery Hospital in Chennai launched the Kauvery Cervical Cancer Screening Program, aiming to address the global health concern of cervical cancer. Despite the World Health Organizations’ recommendation of 70% screening for women, only 1.9 per cent undergo it in India. The program aims to significantly reduce the impact of cervical cancer for women in Tamil Nadu, which is the second leading cause of cancer among women in the state. By increasing awareness and facilitating access to screening services, Kauvery Hospital believes it can significantly reduce the burden of cervical cancer in the region and save lives.
Competitive Landscape Analysis
The competitive landscape of the uterine cancer diagnostic testing market is characterized by the presence of several key players striving to develop innovative diagnostic solutions. These companies have a strong market presence and are actively involved in research and development efforts to introduce novel diagnostic procedures and expand their product lines. The market is moderately competitive, with global players dominating the market. The adoption of novel diagnostic products and significant research and development efforts have helped these companies maintain a strong position in the market.
Key Market Companies
- Sysmex Corporation
- AbbVie Inc.
- Merck & Co. Ltd
- Pfizer Inc.
- Becton Dickinson and Company
- Bristol-Myers Squibb Company
- Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Abbott Laboratories Inc.
- Illumina Inc
- bioMrieux SA
- Takeda Pharmaceutical Company Limited
An Expert’s Eye
- The uterine cancer diagnostic testing market is poised for substantial growth in the light of the increasing incidence of uterine cancer, particularly endometrial cancer, coupled with the growing awareness about early detection.
- Early and accurate diagnosis of uterine cancer is crucial for effective treatment, and technological advancements will play a pivotal role in improving patient outcomes.
- Significant investments in research and development are likely to improve diagnostic accuracy and sensitivity, which would drive the market forward.
- The integration of AI and ML will revolutionize image analysis and data interpretation.
- While challenges such as reimbursement issues and access to testing in underserved populations persist, the overall performance of the market looks optimistic.
Uterine Cancer Diagnostic Testing Market Segmentation :
By Type
- Blood test
- Endometrial biopsy
- Imaging
- Others
By End User
- Hospitals
- Diagnostic centers
- Cancer research centers
- Others
By Region
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
1. Executive Summary
1.1. Global Uterine Cancer Diagnostic Testing Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Uterine Cancer Diagnostic Testing Market Outlook, 2019 - 2031
3.1. Global Uterine Cancer Diagnostic Testing Market Outlook, by Cancer Type, Value (US$ Bn), 2019 - 2031
3.1.1. Key Highlights
3.1.1.1. Endometrial Carcinoma
3.1.1.2. Uterine Sarcoma
3.2. Global Uterine Cancer Diagnostic Testing Market Outlook, by Diagnostic test type, Value (US$ Bn), 2019 - 2031
3.2.1. Key Highlights
3.2.1.1. Ultrasound Scanning
3.2.1.1.1. Abdominal Ultrasound Scanning
3.2.1.1.2. Transvaginal Ultrasound Scanning
3.2.1.2. Biopsy Procedures
3.2.1.2.1. Endometrial Biopsy
3.2.1.2.2. Hysteroscopy
3.2.1.2.3. Dilation & Curettage
3.2.1.3. Blood Tests
3.2.1.3.1. Complete Blood Count
3.2.1.3.2. CA125 Marker Blood Test
3.3. Global Uterine Cancer Diagnostic Testing Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
3.3.1. Key Highlights
3.3.1.1. Hospitals
3.3.1.2. Ambulatory Surgical Centers
3.3.1.3. Cancer Research Institutes
3.3.1.4. Specialized Clinics
3.3.1.5. Diagnostic Laboratories
3.3.1.6. Others
3.4. Global Uterine Cancer Diagnostic Testing Market Outlook, by Region, Value (US$ Bn), 2019 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Uterine Cancer Diagnostic Testing Market Outlook, 2019 - 2031
4.1. North America Uterine Cancer Diagnostic Testing Market Outlook, by Cancer Type, Value (US$ Bn), 2019 - 2031
4.1.1. Key Highlights
4.1.1.1. Ultrasound Scanning
4.1.1.1.1. Abdominal Ultrasound Scanning
4.1.1.1.2. Transvaginal Ultrasound Scanning
4.1.1.2. Biopsy Procedures
4.1.1.2.1. Endometrial Biopsy
4.1.1.2.2. Hysteroscopy
4.1.1.2.3. Dilation & Curettage
4.1.1.3. Blood Tests
4.1.1.3.1. Complete Blood Count
4.1.1.3.2. CA125 Marker Blood Test
4.2. North America Uterine Cancer Diagnostic Testing Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
4.2.1. Key Highlights
4.2.1.1. Hospitals
4.2.1.2. Ambulatory Surgical Centers
4.2.1.3. Cancer Research Institutes
4.2.1.4. Specialized Clinics
4.2.1.5. Diagnostic Laboratories
4.2.1.6. Others
4.3. North America Uterine Cancer Diagnostic Testing Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
4.3.1. Key Highlights
4.3.1.1. U.S. Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
4.3.1.2. U.S. Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
4.3.1.3. U.S. Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
4.3.1.4. Canada Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
4.3.1.5. Canada Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
4.3.1.6. Canada Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
4.3.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Uterine Cancer Diagnostic Testing Market Outlook, 2019 - 2031
5.1. Europe Uterine Cancer Diagnostic Testing Market Outlook, by Cancer Type, Value (US$ Bn), 2019 - 2031
5.1.1. Key Highlights
5.1.1.1. Ultrasound Scanning
5.1.1.1.1. Abdominal Ultrasound Scanning
5.1.1.1.2. Transvaginal Ultrasound Scanning
5.1.1.2. Biopsy Procedures
5.1.1.2.1. Endometrial Biopsy
5.1.1.2.2. Hysteroscopy
5.1.1.2.3. Dilation & Curettage
5.1.1.3. Blood Tests
5.1.1.3.1. Complete Blood Count
5.1.1.3.2. CA125 Marker Blood Test
5.2. Europe Uterine Cancer Diagnostic Testing Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
5.2.1. Key Highlights
5.2.1.1. Hospitals
5.2.1.2. Ambulatory Surgical Centers
5.2.1.3. Cancer Research Institutes
5.2.1.4. Specialized Clinics
5.2.1.5. Diagnostic Laboratories
5.2.1.6. Others
5.3. Europe Uterine Cancer Diagnostic Testing Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
5.3.1. Key Highlights
5.3.1.1. Germany Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
5.3.1.2. Germany Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
5.3.1.3. Germany Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
5.3.1.4. U.K. Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
5.3.1.5. U.K. Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
5.3.1.6. U.K. Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
5.3.1.7. France Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
5.3.1.8. France Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
5.3.1.9. France Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
5.3.1.10. Italy Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
5.3.1.11. Italy Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
5.3.1.12. Italy Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
5.3.1.13. Turkey Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
5.3.1.14. Turkey Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
5.3.1.15. Turkey Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
5.3.1.16. Russia Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
5.3.1.17. Russia Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
5.3.1.18. Russia Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
5.3.1.19. Rest of Europe Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
5.3.1.20. Rest of Europe Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
5.3.1.21. Rest of Europe Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
5.3.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Uterine Cancer Diagnostic Testing Market Outlook, 2019 - 2031
6.1. Asia Pacific Uterine Cancer Diagnostic Testing Market Outlook, by Cancer Type, Value (US$ Bn), 2019 - 2031
6.1.1. Key Highlights
6.1.1.1. Ultrasound Scanning
6.1.1.1.1. Abdominal Ultrasound Scanning
6.1.1.1.2. Transvaginal Ultrasound Scanning
6.1.1.2. Biopsy Procedures
6.1.1.2.1. Endometrial Biopsy
6.1.1.2.2. Hysteroscopy
6.1.1.2.3. Dilation & Curettage
6.1.1.3. Blood Tests
6.1.1.3.1. Complete Blood Count
6.1.1.3.2. CA125 Marker Blood Test
6.2. Asia Pacific Uterine Cancer Diagnostic Testing Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
6.2.1. Key Highlights
6.2.1.1. Hospitals
6.2.1.2. Ambulatory Surgical Centers
6.2.1.3. Cancer Research Institutes
6.2.1.4. Specialized Clinics
6.2.1.5. Diagnostic Laboratories
6.2.1.6. Others
6.3. Asia Pacific Uterine Cancer Diagnostic Testing Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
6.3.1. Key Highlights
6.3.1.1. China Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
6.3.1.2. China Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
6.3.1.3. China Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
6.3.1.4. Japan Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
6.3.1.5. Japan Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
6.3.1.6. Japan Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
6.3.1.7. South Korea Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
6.3.1.8. South Korea Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
6.3.1.9. South Korea Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
6.3.1.10. India Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
6.3.1.11. India Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
6.3.1.12. India Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
6.3.1.13. Southeast Asia Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
6.3.1.14. Southeast Asia Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
6.3.1.15. Southeast Asia Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
6.3.1.16. Rest of Asia Pacific Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
6.3.1.17. Rest of Asia Pacific Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
6.3.1.18. Rest of Asia Pacific Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
6.3.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Uterine Cancer Diagnostic Testing Market Outlook, 2019 - 2031
7.1. Latin America Uterine Cancer Diagnostic Testing Market Outlook, by Cancer Type, Value (US$ Bn), 2019 - 2031
7.1.1. Key Highlights
7.1.1.1. Ultrasound Scanning
7.1.1.1.1. Abdominal Ultrasound Scanning
7.1.1.1.2. Transvaginal Ultrasound Scanning
7.1.1.2. Biopsy Procedures
7.1.1.2.1. Endometrial Biopsy
7.1.1.2.2. Hysteroscopy
7.1.1.2.3. Dilation & Curettage
7.1.1.3. Blood Tests
7.1.1.3.1. Complete Blood Count
7.1.1.3.2. CA125 Marker Blood Test
7.2. Latin America Uterine Cancer Diagnostic Testing Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
7.2.1. Key Highlights
7.2.1.1. Hospitals
7.2.1.2. Ambulatory Surgical Centers
7.2.1.3. Cancer Research Institutes
7.2.1.4. Specialized Clinics
7.2.1.5. Diagnostic Laboratories
7.2.1.6. Others
7.3. Latin America Uterine Cancer Diagnostic Testing Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
7.3.1. Key Highlights
7.3.1.1. Brazil Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
7.3.1.2. Brazil Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
7.3.1.3. Brazil Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
7.3.1.4. Mexico Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
7.3.1.5. Mexico Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
7.3.1.6. Mexico Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
7.3.1.7. Argentina Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
7.3.1.8. Argentina Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
7.3.1.9. Argentina Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
7.3.1.10. Rest of Latin America Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
7.3.1.11. Rest of Latin America Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
7.3.1.12. Rest of Latin America Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
7.3.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Uterine Cancer Diagnostic Testing Market Outlook, 2019 - 2031
8.1. Middle East & Africa Uterine Cancer Diagnostic Testing Market Outlook, by Cancer Type, Value (US$ Bn), 2019 - 2031
8.1.1. Key Highlights
8.1.1.1. Ultrasound Scanning
8.1.1.1.1. Abdominal Ultrasound Scanning
8.1.1.1.2. Transvaginal Ultrasound Scanning
8.1.1.2. Biopsy Procedures
8.1.1.2.1. Endometrial Biopsy
8.1.1.2.2. Hysteroscopy
8.1.1.2.3. Dilation & Curettage
8.1.1.3. Blood Tests
8.1.1.3.1. Complete Blood Count
8.1.1.3.2. CA125 Marker Blood Test
8.2. Middle East & Africa Uterine Cancer Diagnostic Testing Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
8.2.1. Key Highlights
8.2.1.1. Hospitals
8.2.1.2. Ambulatory Surgical Centers
8.2.1.3. Cancer Research Institutes
8.2.1.4. Specialized Clinics
8.2.1.5. Diagnostic Laboratories
8.2.1.6. Others
8.3. Middle East & Africa Uterine Cancer Diagnostic Testing Market Outlook, by Country, Value (US$ Bn), 2019 - 2031
8.3.1. Key Highlights
8.3.1.1. GCC Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
8.3.1.2. GCC Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
8.3.1.3. GCC Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
8.3.1.4. South Africa Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
8.3.1.5. South Africa Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
8.3.1.6. South Africa Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
8.3.1.7. Egypt Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
8.3.1.8. Egypt Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
8.3.1.9. Egypt Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
8.3.1.10. Nigeria Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
8.3.1.11. Nigeria Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
8.3.1.12. Nigeria Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
8.3.1.13. Rest of Middle East & Africa Uterine Cancer Diagnostic Testing Market by Cancer Type, Value (US$ Bn), 2019 - 2031
8.3.1.14. Rest of Middle East & Africa Uterine Cancer Diagnostic Testing Market by Diagnostic test type, Value (US$ Bn), 2019 - 2031
8.3.1.15. Rest of Middle East & Africa Uterine Cancer Diagnostic Testing Market End User, Value (US$ Bn), 2019 - 2031
8.3.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Cancer Type vs End User Heatmap
9.2. Manufacturer vs End User Heatmap
9.3. Company Market Share Analysis, 2022
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. F. Hoffmann-La Roche Ltd.
9.5.1.1. Company Overview
9.5.1.2. Cancer Type Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. Siemens Healthcare Private Limited
9.5.2.1. Company Overview
9.5.2.2. Cancer Type Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Abbott
9.5.3.1. Company Overview
9.5.3.2. Cancer Type Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Danaher Corporation
9.5.4.1. Company Overview
9.5.4.2. Cancer Type Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. bioMérieux S. A.
9.5.5.1. Company Overview
9.5.5.2. Cancer Type Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Becton Dickinson and Company
9.5.6.1. Company Overview
9.5.6.2. Cancer Type Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Merck & Co., Inc.
9.5.7.1. Company Overview
9.5.7.2. Cancer Type Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Takeda Pharmaceutical Company Limited
9.5.8.1. Company Overview
9.5.8.2. Cancer Type Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. GlaxoSmithKline Plc.
9.5.9.1. Company Overview
9.5.9.2. Cancer Type Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Novartis AG
9.5.10.1. Company Overview
9.5.10.2. Cancer Type Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. Ariad Pharmaceuticals, Inc.
9.5.11.1. Company Overview
9.5.11.2. Cancer Type Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development
9.5.12. Sanofi
9.5.12.1. Company Overview
9.5.12.2. Cancer Type Portfolio
9.5.12.3. Financial Overview
9.5.12.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations
|
BASE YEAR |
HISTORICAL DATA |
FORECAST PERIOD |
UNITS |
|||
 |
2023 |
 |
2019 - 2023 |
 |
2024 - 2031 |
Value: US$ Billion |
|
REPORT FEATURES |
DETAILS |
|
Type Coverage |
|
|
End User Coverage |
|
|
Geographical Coverage |
|
|
Leading Companies |
|
|
Report Highlights |
Key Market Indicators, Macro-micro economic impact analysis, Technological Roadmap, Key Trends, Driver, Restraints, and Future Opportunities & Revenue Pockets, Porter’s 5 Forces Analysis, Historical Trend (2019-2021), Market Estimates and Forecast, Market Dynamics, Industry Trends, Competition Landscape, Category, Region, Country-wise Trends & Analysis, COVID-19 Impact Analysis (Demand and Supply Chain) |
Quality assured
